Compare EVV & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVV | GERN |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 911.0M |
| IPO Year | 2003 | 1996 |
| Metric | EVV | GERN |
|---|---|---|
| Price | $9.08 | $1.54 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 413.7K | ★ 11.2M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,065,000.00 |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.97 | $1.04 |
| 52 Week High | $10.41 | $2.01 |
| Indicator | EVV | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 53.85 |
| Support Level | $8.97 | $1.42 |
| Resistance Level | $9.32 | $1.68 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 19.08 | 60.33 |
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.